Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pennogenin 3-O-beta-chacotrioside, also known as Polyphyllin VII, is a steroidal saponin isolated from the rhizomes of *Paris polyphylla*, a plant widely used in traditional Chinese medicine for its anti-cancer properties. It has been identified as a primary bioactive constituent in the ethanolic extract of *P. polyphylla* (EEPP) and is being investigated for its efficacy against colorectal cancer. The compound induces cell death in human colorectal carcinoma cells, such as the DLD-1 line, by upregulating autophagy markers. This mechanism of action is notably independent of p53 and caspase-3 activation, suggesting a non-apoptotic pathway for tumor suppression. Furthermore, pennogenin 3-O-beta-chacotrioside has demonstrated synergistic potential when used in combination with the chemotherapeutic drug doxorubicin, significantly enhancing cytotoxicity in tumor cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pennogenin 3-O-beta-chacotrioside.